FHR4-based immunoconjugates direct complement-dependent cytotoxicity and phagocytosis towards HER2-positive cancer cells

Molecular Oncology
Carole Seguin-DevauxXavier Dervillez

Abstract

Directing selective complement activation towards tumour cells is an attractive strategy to promote their elimination. In the present work, we have generated heteromultimeric immunoconjugates that selectively activate the complement alternative pathway (AP) on tumour cells. We used the C4b-binding protein C-terminal-α-/β-chain scaffold for multimerisation to generate heteromultimeric immunoconjugates displaying (a) a multivalent-positive regulator of the AP, the human factor H-related protein 4 (FHR4) with; (b) a multivalent targeting function directed against erbB2 (HER2); and (c) a monovalent enhanced GFP tracking function. Two distinct VH H targeting two different epitopes against HER2 and competing either with trastuzumab or with pertuzumab-recognising epitopes [VH H(T) or VH H(P)], respectively, were used as HER2 anchoring moieties. Optimised high-FHR4 valence heteromultimeric immunoconjugates [FHR4/VH H(T) or FHR4/VH H(P)] were selected by sequential cell cloning and a selective multistep His-Trap purification. Optimised FHR4-heteromultimeric immunoconjugates successfully overcame FH-mediated complement inhibition threshold, causing increased C3b deposition on SK-OV-3, BT474 and SK-BR3 tumour cells, and increased formatio...Continue Reading

References

Jan 1, 1980·Molecular Immunology·R A Harrison, P J Lachmann
Jul 1, 1997·Nature Biotechnology·R E KontermannG Winter
Jan 21, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·S OudinJ H Cohen
Feb 13, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·E E IdusogieM G Mulkerrin
Feb 27, 2001·Journal of Virology·M HildingerD von Laer
Mar 24, 2004·Trends in Immunology·Kyra A GeldermanArko Gorter
Jan 10, 2008·International Journal of Cancer. Journal International Du Cancer·Ewa WilczekGrzegorz M Wilczynski
Aug 30, 2008·Molecular Cancer Therapeutics·John O RichardsJohn R Desjarlais
Jun 12, 2009·Journal of Hematology & Oncology·Godfrey Chi-Fung ChanDaniel Man-Yuen Sze
Jun 29, 2010·Molecular Immunology·Viviana P FerreiraClaudio Cortés
Jan 5, 2011·Frontiers in Bioscience (Landmark Edition)·Magdalena WiniarskaJakub Golab
Mar 15, 2013·Proceedings of the National Academy of Sciences of the United States of America·Elena Goicoechea de JorgeSusan M Lea
Nov 19, 2013·FEBS Letters·Darrick Carter, André Lieber
Mar 15, 2014·Science·Christoph A DiebolderPaul W H I Parren
Jun 19, 2014·Critical Reviews in Immunology·Stefanie DererThomas Valerius
Aug 22, 2014·Clinical and Vaccine Immunology : CVI·Jutamas ShaughnessySanjay Ram
May 17, 2015·Trends in Immunology·Mihály JózsiSantiago Rodríguez de Córdoba
Jun 28, 2017·CPT: Pharmacometrics & Systems Pharmacology·Josiah T Ryman, Bernd Meibohm
Jan 10, 2018·Seminars in Immunopathology·B Paul Morgan, David Kavanagh
May 3, 2018·Frontiers in Immunology·Richard B PouwTaco W Kuijpers
May 3, 2019·Nature Reviews. Immunology·Edimara S ReisJohn D Lambris

❮ Previous
Next ❯

Methods Mentioned

BETA
transfection
flow cytometry
chips
density gradient centrifugation
confocal microscopy
Surface plasmon resonance

Software Mentioned

GraphPad
BIAevaluation
graphpad prism
chemostar imager

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Clinical Advances in Hematology & Oncology : H&O
Debu Tripathy
Targeted Diagnosis and Therapy
G A PieterszI F McKenzie
Targeted Diagnosis and Therapy
J B Cannon, H W Hui
Cancer Chemotherapy and Biological Response Modifiers
R W Baldwin, V S Byers
Cancer Chemotherapy and Biological Response Modifiers
R W BaldwinM V Pimm
© 2021 Meta ULC. All rights reserved